Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
163.10
+1.92 (1.19%)
At close: Feb 13, 2026, 4:00 PM EST
164.00
+0.90 (0.55%)
After-hours: Feb 13, 2026, 7:44 PM EST
Novartis AG Market Cap
Novartis AG has a market cap or net worth of $313.57 billion as of February 13, 2026. Its market cap has increased by 49.73% in one year.
Market Cap
313.57B
Enterprise Value
338.66B
1-Year Change
49.73%
Ranking
Category
Stock Price
$163.10
Market Cap Chart
Since April 11, 2001, Novartis AG's market cap has increased from $116.62B to $313.57B, an increase of 168.89%. That is a compound annual growth rate of 4.06%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 13, 2026 | 311.22B | 17.20% |
| Dec 31, 2025 | 265.54B | 36.49% |
| Dec 31, 2024 | 194.55B | -6.26% |
| Dec 29, 2023 | 207.54B | 5.57% |
| Dec 30, 2022 | 196.59B | 0.47% |
| Dec 31, 2021 | 195.68B | -9.46% |
| Dec 31, 2020 | 216.12B | -1.25% |
| Dec 31, 2019 | 218.84B | 10.05% |
| Dec 31, 2018 | 198.86B | -0.23% |
| Dec 29, 2017 | 199.33B | 15.27% |
| Dec 30, 2016 | 172.91B | -16.21% |
| Dec 31, 2015 | 206.38B | -8.20% |
| Dec 31, 2014 | 224.80B | 15.54% |
| Dec 31, 2013 | 194.57B | 27.72% |
| Dec 31, 2012 | 152.34B | 16.39% |
| Dec 30, 2011 | 130.89B | -2.38% |
| Dec 31, 2010 | 134.07B | 8.76% |
| Dec 31, 2009 | 123.28B | 9.40% |
| Dec 31, 2008 | 112.68B | -11.65% |
| Dec 31, 2007 | 127.53B | -4.95% |
| Dec 29, 2006 | 134.18B | 5.35% |
| Dec 30, 2005 | 127.36B | 2.12% |
| Dec 31, 2004 | 124.72B | 9.81% |
| Dec 31, 2003 | 113.58B | 7.17% |
| Dec 31, 2002 | 105.97B | 0.63% |
View and export this data all the way back to 2001. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Johnson & Johnson | 586.69B |
| AbbVie | 409.15B |
| AstraZeneca | 319.57B |
| Merck & Co. | 301.34B |
| Novo Nordisk | 219.20B |
| Amgen | 198.80B |
| Gilead Sciences | 192.28B |
| Pfizer | 156.81B |